Samsung Bioepis Co. Ltd. reports that the U.S. FDA has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult...
Costly Biologics to treat diseases such as autoimmune diseases have flooded the market over the past couple of decades. Prominently advertised on television ads promising improved gastrointestinal symptoms or clearer skin with “sexy elbows.” They are effective for...
